08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

Alferon LDO: Phase II planned

FDA lifted a November 2009 clinical hold on a double-blind, placebo-controlled, dose-ranging Phase II trial in >200 subjects to evaluate Alferon LDO after Hemispherx resolved issues related to additional chemistry, manufacturing and controls (CMC) information....
08:00 , Dec 6, 2004 |  BC Week In Review  |  Clinical News

Alferon LDO: Start Phase I/II

HEB will begin this month an open-label, dose-ranging, Chinese PhI/II trial in 10 asymptomatic subjects with recent exposure to a person with SARS or possible SARS infection. The subjects will receive Alferon 650 IU or...
08:00 , Mar 8, 2004 |  BC Week In Review  |  Clinical News

Alferon LDO: Phase II

HEB will begin this month a 6-week, open-label Phase II trial in 60 patients. Hemispherx Biopharma Inc. (HEB), Philadelphia, Penn.   Product: Alferon LDO   Business: Infectious   Molecular target: Type I interferon (IFN) receptor...
08:00 , Mar 2, 2004 |  BC Extra  |  Clinical News

Hemispherx to start HIV Phase II

This month, HEB will begin an open-label Phase II trial of its Alferon LDO low dose interferon alpha-n3 in 60 patients with asymptomatic HIV. The primary endpoint of the six-week trial will be an increase...
08:00 , Mar 17, 2003 |  BC Week In Review  |  Company News

Hemispherx, Interferon deal

HEB acquired certain interferon IP assets from Interferon Sciences, including rights to Alferon N interferon alpha injection, which is marketed to treat venereal warts, as well as rights to Alferon N Gel and Alferon LDO...
07:00 , Jun 10, 1996 |  BC Week In Review  |  Clinical News

Alferon LDO: IFSC began participation in a Phase III trial

Antiviral drugs and agents to treat opportunistic infections will be allowed to be continued during the trial. Participants will have CD4 counts between 50 and 350. Study medications will be given for six months, with...